** Shares of U.S. drugmaker Eli Lilly LLY.N fall 1.5% to $856.37 premarket
** Danish rival Novo Nordisk NOVOb.CO reports late-stage data for its experimental next-generation weight-loss drug, CagriSema
** Says CagriSema helped overweight patients with type 2 diabetes (T2D) cut their weight by 15.7% after 68 weeks compared to 3.1% with placebo
** This compares to absolute weight loss of up to ~15.5% shown by LLY's obesity drug Zepbound in T2D patients at week 68 in a late-stage study - Brokerage Leerink Partners
** The CagriSema weight loss data appears a comparable cross-trial to LLY's Zepbound, brokerage says
** Up to last close, LLY stock had risen 11.5% in the past 12 months
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。